In adults with obesity without diabetes, tirzepatide 5, 10 and 15 mg once weekly reduced body weight at week 72 by 15.0%, 19.5% and 20.9%, versus 3.1% with placebo, a significant difference for every dose.
In plain wordsIn adults with obesity, weight loss after 72 weeks was greater with tirzepatide than with placebo.
- Peptide
- Tirzepatide
- Outcome
- DecreasePercentage change in body weight at week 72
- Study
n = 2,539
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Body weight · Metabolic and weight
- Studied dose
- 5 mg, 10 mg or 15 mg once weekly · subcutaneous · 72 weeks, including a 20-week dose-escalation periodAs given in this study (human).
Measurements
- Mean percentage weight reduction at week 72
- 15%
- tirzepatide 5 mg
- Mean percentage weight reduction at week 72
- 19.5%
- tirzepatide 10 mg
- Mean percentage weight reduction at week 72
- 20.9%
- tirzepatide 15 mg
- Mean percentage weight reduction at week 72
- 3.1%
- placebo
Source sentences
The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.0…
1 context sentence(design, population, supporting numbers)
we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg,…